Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and ...